本次大会由Biocytogen和AcroBiosystem联合主办，围绕生物医药以及抗体药物的发现与发展，致力于为生物医药产业做出更多的贡献。会议于美国时间2019年6月13日下午1-6点在波士顿召开，届时欢迎大家莅临参会。
Free to attend, light dinner will be provided. Join Biocytogen and AcroBiosystem to learn more about the cutting-edge technologies and latest research in biologic drug development. The symposium is co-organized by Biocytogenand AcroBiosystem, focusing mainly on therapeutic antibody and biologic drug discovery and development.
Theme:Future of Biologic Drug Discovery and Development
Time:June 13th, 1:00 PM - 6:00 PM
Location:Residence Inn Boston Cambridge, 120 Broadway, Six Cambridge Center, Cambridge, MA
Confirmed Speakers
Chun-Nan Chen
CEO and CSO, Single Cell Technology
Qingcong Lin
CEO, Biocytogen Boston Corp
Stephen Gillies
CSO, LinkedUp Bioscience Inc
Johanna Lahdenranta
Director of In Vivo Pharmacology, Bicycle Therapeutics
Xiaodong Li
Associate of Patent and Intellectual Property, Choate, Hall Stewart LLP
Agenda
1:00 PM - 1:20 PM
Registration
1:20 PM - 1:30 PM
Welcome Remark
1:30 PM - 2:00 PM
Introducing AbTheneum, A High Throughput and Data-rich Antibody Discovery Platform by Single Cell Technology
Chun-Nan Chen, CEO and CSO, Single Cell Technology
Named after an institution of great knowledge, AbTheneum is Single Cell Technology s antibody discovery platform. Deploying AbTheneum , we screen thousands of antibody-secreting cells for binding characteristics and sequence all the cells to return native heavy and light chain sequence pairs correlated with the binding activity for each antibody from single cells. AbTheneum screening assay is flexible and can be customized for any target to find cross-reactivity, epitope specificity, and more. Case studies will be shown for anti-BCMA and anti-FOLR1 antibody leads discovered using AbTheneum and their validation data. The discovery of these high-quality and therapeutically relevant antibody candidates highlights the power of AbTheneum .
2:00 PM - 2:30 PM
Accelerating Therapeutic Antibody Candidate Discovery using Biocytogen Humanized Mouse Models
Qingcong Lin, CEO, Biocytogen Boston Corp
The traditional therapeutic antibody discovery is a lengthy, multi-staged process from hit generation, lead screening, optimization to candidate selection. Depending on surrogate antibodies for efficacy tests in animal models has significantly constrained the therapeutic antibody discovery. This presentation will discuss three approaches to expedite the process. First, Biocytogen has generated thirty+ IO checkpoint humanized GEMM, enabling direct testing of anti-human antibodies in mice without depending on mouse cross-reactive antibody candidates. We have also created human CD3 knock-in mice for testing T cell-engaging bispecific antibodies. Second, our proprietary immunodeficient B-NDG and series of B-NDG variant mice are excellent host for engraftment of human PBMC and CD34+ hematopoietic stem cells and allow testing anti-human antibody candidate efficacy and safety. Finally, we have generated RenMab mice, by introducing the complete human heavy chain and light chain V(D)J regions to replace the mouse counterpart loci. A case study, where we considerably shortened the hit to lead process by conducting high-throughput in vivo efficacy-based lead identification using our humanized mice will also be presented.
2:30 PM - 3:00 PM
Humanized Mice for Studies of Immunocytokine Mono and Combi-therapies
Stephen Gillies, CSO, LinkedUp Bioscience IncAntibody-cytokine fusion proteins (immunocytokines or IC) target the tumor microenvironment where they stimulate a cascade of immune responses based on their interaction with resident tumor, stroma and infiltrating lymphocytes, macrophage and myeloid cells. The goal is to overcome this immune suppressive environment. Due to species specificity of cytokine and cytokine receptor interactions, the best way is to use murine cytokines in syngeneic tumor models or to use humanized NOG mice with the all human antibody and cytokine molecules being developed as potential drugs. Many years ago, in collaboration with Jackson Labs and the University of Tuebingen, we developed models in which CD34+ human hematopoietic stem cells were adoptively transferred into irradiated NOG mice and given weekly doses of long-lasting IL7 (Fc-IL7). This resulted in mice with high numbers of human B, NK and T cells that quickly develop diverse TCR repertoires and have since been shown to be highly functional in IC-induced anti-tumor efficacy. One such IC, NHS-IL12, contains two molecules of species-specific human IL12 and targets DNA that is released into the necrotic regions of all solid tumors, independent of species. Studies include combination therapies with local radiation or with other cytokines leading to some surprising results.3:00 PM - 3:30 PM
Coffee Break and Networking
3:30 PM - 4:00 PM
Activation of CD137 Using Multivalent and Tumor Targeted Bicyclic Peptides
Johanna Lahdenranta, Director of In Vivo Pharmacology, Bicycle Therapeutics
4:00 PM - 4:30 PM
Patent Portfolio Development for Biologic Products
Xiaodong Li,Associate of Patent and Intellectual Property, Choate, Hall Stewart LLPBiological products are typically protected by patent portfolios comprising a number of patents. Using specific products as examples, Xiaodong will discuss how to use different types of patent filings and claims to provide layered protection for biological products and how to maximize their patent protection. He will share his experience on how to identify inventions at various development and commercial stages and how to protect them accordingly.4:30 PM 6:00 PM
Dinner Reception (Light dinner will be provided)
To register for the symposium, pleasego to register
